Technology Area: Drug Development
206 Results for 'Drug Development'
- Technologies (13)
- Team (0)
- News (146)
- Events (0)
- Multimedia (47)
- Publications (0)
- Jobs (0)
Technologies 13
-
CogniXense – A high-throughput cognitive screen for modeling disorders on-the-fly
There are more than 6,000 known single-gene disorders, in which a disruption to one gene out of the 20,000 in the human genome is enough to cause significant health effects. In order to study these disorders and develop treatments, a given genetic mutation must first be induced in a large number of animal models (usually... -
abbieSense Anaphylaxis Diagnostic
The molecule histamine plays a primary role in the anaphylaxis reaction, which is a major cause of illness and death in people with severe allergies. Histamine is a very small molecule composed of only seventeen atoms, making it a challenging target to detect. To date, no diagnostic test exists that can measure histamine levels accurately... -
Customizable scaffolds for faster, higher-quality T cell production
Immunotherapy, or tweaking the body’s own immune system to treat disease, is attracting significant attention in the medical field for its potential to offer long-lasting cures with fewer side effects than chemotherapy or other drugs. One type of immunotherapy involves isolating T cells (a type of white blood cell) from a patient’s body, sometimes modifying... -
Human Organs-on-Chips
Clinical studies take years to complete and testing a single compound can cost more than $2 billion. Meanwhile, innumerable animal lives are lost, and the process often fails to predict human responses because traditional animal models often do not accurately mimic human pathophysiology. For these reasons, there is a broad need for alternative ways to... -
Microfluidic encapsulation for subcutaneous delivery of viscous drugs
Because of their large molecular sizes and properties, biologic drugs, be it in the form of monoclonal antibodies that target disease-associated molecules or active proteins and enzymes that may correct deficiencies in the human body, have proven difficult to deploy in many cases. Their therapeutic effects on target cells and tissues often require high and... -
A broad strategy to reduce the toxicity of protein drugs
Therapeutic variants of the natural hormone erythropoietin (EPO) which is produced in the kidney to boost the production of red blood cells are commonly used to treat anemias stemming from kidney disease, chemotherapy and other complications. However, many drugs that are based on therapeutic proteins, including EPO, often cause unwanted side effects because they not...
News 146
Multimedia 47
-
Video/AnimationSABER-FISH: Enabling the sensitive and multiplexed detection of nucleic acids within thick tissuesThis animation shows how SABER-FISH uses a suite of DNA nanotechnological methods that together enable the sensitive and multiplexed detection of DNA and RNA targets within cells and thick tissues. Credit: Wyss Institute at Harvard University -
Video/AnimationKidney Organiods: Flow-Enhanced Vascularization and Maturation In VitroThis video explains how the collaborative project created vascularized kidney organoids and how they advance the field of tissue engineering. Credit: Wyss Institute at Harvard University. -
Video/AnimationabbieSenseabbieSense is a Wyss technology that can detect histamine levels in human body fluids and determine the severity of an allergic reaction, which could help save the lives of patients with severe allergies. Credit: Wyss Institute at Harvard University -
Audio/PodcastDisruptive: Art Advances ScienceIn this episode of Disruptive, Wyss Institute Founding Director Don Ingber and Staff Scientist Charles Reilly discuss their process creating The Beginning, a short film inspired by Star Wars, to better communicate science to the public…and how they made a scientific discovery along the way. To make The Beginning, film industry visual effects and animation... -
Video/AnimationNew Wyss Institute Initiative – 3D Organ EngineeringWyss Institute Core Faculty members Christopher Chen and Jennifer Lewis describe the Wyss Institute’s new initiative focused on organ engineering, which leverages our expertise in biomaterials, tissue engineering, three dimensional biofabrication, and stem cell development. -
Audio/PodcastDisruptive: Cancer Vaccine and Immuno-MaterialsImmunotherapy – treatment that uses the body’s own immune system to help fight disease – has groundbreaking and life-saving implications. In an effort to make immunotherapy more effective, Wyss Institute researchers are developing new immuno-materials, which help modulate immune cells to treat or diagnose disease. In this episode of Disruptive, Dave Mooney, Wyss Core Faculty...